

Datasheet: MCA2260P

Description:	RAT ANTI RITUXIMAB:HRP
Specificity:	RITUXIMAB
Other names:	MabThera , Rituxan
Format:	HRP
Product Type:	Monoclonal Antibody
Clone:	MB2A4
Isotype:	IgG2a
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			1/20000 - 1/200000

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use

Product Form	Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution	Phosphate buffered saline
Preservative	0.01% Thiomersal
Stabilisers	HRP Stabiliser (BUF052A)
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	F(ab) ₂ fragment of Rituximab
Fusion Partners	Spleen cells from immunised rats were fused with cells of the NS-1 mouse myeloma cell line

Specificity

Rat Anti-Rituximab Antibody, clone MB2A4, is an anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug rituximab. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays. Rat Anti-Rituximab Antibody, clone MB2A4, is specific for rituximab and does not recognize other CD20 antibodies. Clone MB2A4 has been used in ELISA to monitor the levels of rituximab in patient serum following therapy ([Cragg et al. 2004](#) and [Hampson et al. 2010](#)).

Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line,

however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the Anti-Rituximab Antibody to cell bound rituximab ([Beum et al. 2004](#)). Inhibition experiments carried out with Daudi cells demonstrated that this antibody is inhibitory at a ratio of 5:1 antibody:rituximab, but does not inhibit rituximab binding to CD20 at a ratio of 1:1.

Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.

[View a summary of all Anti-Rituximab Antibodies.](#)

ELISA

This product may be used in a direct ELISA or as a detection reagent in a sandwich ELISA together with [HCA186](#) as the capture reagent. Protocol: [PK bridging ELISA to measure free drug](#)

References

1. Cragg, M. S. *et al.* (2004) A new anti-idiotypic antibody capable of binding rituximab on the surface of lymphoma cells. [Blood. 104:2540-2](#)
2. Cragg, M.S. *et al.* (2004) Apparent modulation of CD20 by rituximab: an alternative explanation. [Blood. 103 \(10\): 3989-90; author reply 3990-1.](#)
3. Beum, P.V. *et al.* (2004) Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. [J Immunol Methods. 294 \(1-2\): 37-42.](#)
4. Hampson, G. *et al.* (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. [J Immunol Methods. 360 \(1-2\): 30-8.](#)
5. Blasco, H. *et al.* (2007) Evaluation of a peptide ELISA for the detection of rituximab in serum. [J Immunol Methods. 325: 127-39.](#)
6. Daydé, D. *et al.* (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. [Blood. 113: 3765-72.](#)
7. Aung, T. *et al.* (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. [Proc Natl Acad Sci U S A. 108: 15336-41.](#)
8. Schmidt, E. *et al.* (2009) Immunogenicity of rituximab in patients with severe pemphigus. [Clin Immunol. 132: 334-41.](#)
9. McDonald, V. *et al.* (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. [J Thromb Haemost. 8: 1201-8.](#)
10. Kagan, L. *et al.* (2012) Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. [Pharm Res. 29: 490-499](#)
11. Kagan, L. and Mager, D.E. (2013) Mechanisms of subcutaneous absorption of rituximab in rats. [Drug Metab Dispos. 41: 248-55.](#)
12. Liu, X.F. *et al.* (2012) Validation of a Gyrolab™ assay for quantification of rituximab in human serum. [J Pharmacol Toxicol Methods. 65: 107-14.](#)
13. Kagan, L. *et al.* (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. [Pharm Res. 31: 3265-73.](#)
14. Blasco, H. *et al.* (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. [Fundam Clin Pharmacol. 23: 601-8.](#)
15. Pers, J.O. *et al.* (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. [Arthritis Rheum. 56: 1464-77.](#)
16. Vacher, P. *et al.* (2015) Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. [J Immunol. pii: 1402942.](#)

17. Komori, M. *et al.* (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis [Annals of Clinical and Translational Neurology. Feb 1. \[Epub ahead of print\]](#)
18. Illidge, T.M. *et al.* (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. [Br J Haematol. Feb 5. \[Epub ahead of print\]](#)
19. Lioger, B. *et al.* (2017) Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. [Br J Clin Pharmacol. Feb 23. \[Epub ahead of print\]](#)
20. Kashiwagi, N. *et al.* (2017) Method for measuring anti-drug antibody [US Patent Application US20170315118A1](#)

Storage	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	18 months from date of despatch.
Acknowledgements	Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA. MabThera ® is a registered trademark of Roche in Europe
Health And Safety Information	Material Safety Datasheet documentation #10131 available at: 10131: https://www.bio-rad-antibodies.com/uploads/MSDS/10131.pdf
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

[HUMAN ANTI RITUXIMAB \(HCA061\)](#)

[HUMAN ANTI RITUXIMAB:HRP \(HCA061P\)](#)

[HUMAN ANTI RITUXIMAB \(HCA062\)](#)

[HUMAN ANTI RITUXIMAB:HRP \(HCA062P\)](#)

[HUMAN ANTI RITUXIMAB \(HCA186\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

'M335265:181204'

Printed on 11 Oct 2019